Table I [i] PIO pioglitazone, GLP-1R glucagon-like peptide 1 receptor, SGLT2 sodium-glucose co-transporters 2, TOFO tofogliflozin, SUL sulfonylurea, MET metformin, DAPA dapagliflozin, EXE exenatide, NAFLD non-alcoholic fatty liver disease, T2D type 2 diabetes, A1C glycated hemoglobin, ALT alanine aminotransferase, AST aspartate aminotransferase, -GT gamma-glutamyl transferase, MRI-PDFF MRI-proton density fat fraction, MRE-LSM MR elastography-liver stiffness, RCT randomized controlled trial, EDICT Efficacy and Durability of Initial Combination Therapy, CAP controlled attenuation parameter, LSM liver stiffness measurement, BMI body mass index
Many patients wonder whether bumping up their shot by a single day poses any real risk, but the answer depends on your current dose level and overall treatment plan
Because you can't just throw a sort of set of generic lifestyle suggestions at people, but you really do need to be kind of more targeted about how to help this specific person fight that biological imperative
Contact Novo Nordisk's international patient support at novonordisk.com
By attaching itself to its receptors and activating adenylate cyclase (AC), which raises cAMP levels in the myocardium, glucagon also increases cardiac output
